A new clinical trial has shown that combining Gilead Sciences, Inc. (NASDAQ:GILD)’s Trodelvy with Merck & Co., Inc. (NYSE:MRK ...

Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE ...

Trodelvy, in combination with Merck’s immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Trodelvy, in combination with Keytruda, significantly lowers the risk of progression in triple-negative breast cancer by 35%, ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.